Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
about
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasProfile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaNew developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumabLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsObinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.The clinical development of obinutuzumab for the treatment of follicular lymphoma.Shifting Focus in the Therapeutics of Immunobullous Disease.Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.Obinutuzumab: first global approval.A combinatorial mutagenesis approach for functional epitope mapping on phage-displayed target antigen: application to antibodies against epidermal growth factor.Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity.Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.CD30 as a therapeutic target for lymphoma.Update on obinutuzumab in the treatment of B-cell malignancies.Three major uncertainties in the antibody therapy of cancer.Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.How to successfully patent therapeutic antibodies.Ofatumumab in the treatment of non-Hodgkin's lymphomas.Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Advancing drug delivery systems for the treatment of multiple sclerosis.Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapyRole of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.Targeting B cells in treatment of autoimmunity.Anti-CD20 monoclonal antibodies in multiple sclerosis.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis.Opsoclonus-Myoclonus Syndrome during Rituximab Treatment for Autoimmune Autonomic Ganglionopathy.Monoclonal antibodies targeting CD20.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
P2860
Q26751002-7C371F6E-EE70-447B-984C-883614C469B5Q26781163-59F5A531-6990-4BF9-92F7-2C87DCAA9121Q26801292-93C53B3A-6F93-4BEE-A0A5-EA4A0E94C958Q26849243-93386947-4860-445E-B1E4-E5215A344A85Q33416524-C9147704-99C3-42D1-879F-732256443F77Q33565265-B2F9E813-F986-4783-B2A5-7CFC44B6BEA9Q33737974-FB5C5872-D333-44D7-A438-61D7EF090AC2Q34223866-F5A16206-6115-4804-A9C8-D205D2250228Q34391958-DEC02B34-BB39-4AD9-AD76-FFA33B566B30Q35109650-365A4BDA-20CF-4167-9F2B-954F05533F80Q35110582-506CA4A8-587B-42CE-9C12-372136A5ACA6Q35126754-00678F43-5EBA-42D7-9D44-F9A0106E1C80Q35918945-4FF6FE8F-6DB9-41DE-BEA2-62E999FDA76EQ37380415-B978F55C-2DB9-482D-A09C-638513CB89E8Q37672472-107AA3FC-54B9-4EA2-9AAE-799E6C417F6EQ37741570-389D1756-A307-4BB6-8FB1-6B8DD9707E10Q38138482-F7957ADB-CCDE-47CB-90D3-E68AAB1D7A4FQ38246230-2DDB4644-7442-4D45-83B2-C1E241DA6C6CQ38255786-0F2DDD0C-1C2F-40B7-903C-791E097A34F7Q38317353-55C3BED8-1833-404E-AE6D-6D1C62F160CDQ38329651-082F1864-FBE3-418E-A568-56CF122E0DC9Q38516077-29BACF97-8A2A-4273-8B91-A1AB26708462Q38537523-3A56E352-E3C4-4C0A-B09F-4FD2A9249717Q38542034-6A42E472-14CE-464E-A014-E3427A4C99CEQ38601727-89217E92-EFDA-415C-983A-DF3C0C6CFCB7Q38609620-F327D85C-5276-4919-AE98-711D68AFBEF1Q38665518-0A98C7B9-A3F7-4499-855A-C154E84F6D92Q38711882-86569E49-9837-4686-BC85-289F1CF00076Q38759420-E5B57A1E-6175-4FB9-9EF1-BEAD4DC96896Q38782706-7250A5A7-A18C-4876-B16D-DB72029B7BF5Q38808291-13CE51A9-AF9F-4B18-B17F-9923D1059A36Q38975656-720B7DD9-A477-49A4-9696-8094B922DD7CQ38975695-7D630F74-88BA-4B05-92CE-16EB33DCC69FQ39018189-CA660BB0-02F1-424E-9A0D-792A57963CC8Q39279968-FE0C0988-9343-4B55-B7DD-E998B42A2A92Q39427711-F88C4EEE-ED5C-48C1-A327-6C699B963137Q40993874-0ADF6C0F-1BE8-459C-888C-1787B54731A0Q42906640-840EEA3E-2255-49A6-9252-B06C39C55762Q47221234-F81C3DFD-FDCF-484D-B3D1-403FC7103A49Q47688545-4925F8D7-8CA0-429B-8677-7E66460431CD
P2860
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Epitope interactions of monocl ...... ship to functional properties.
@en
type
label
Epitope interactions of monocl ...... ship to functional properties.
@en
prefLabel
Epitope interactions of monocl ...... ship to functional properties.
@en
P2093
P2860
P356
P1476
Epitope interactions of monocl ...... ship to functional properties.
@en
P2093
Alfred Lammens
Christian Klein
Ekkehard Mössner
Gerhard Niederfellner
Guy Georges
Manfred Schwaiger
Pablo Umaña
Wolfgang Schäfer
P2860
P356
10.4161/MABS.22771
P577
2012-12-04T00:00:00Z